Drugs /

alpha-lactalbumin vaccine

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for alpha-lactalbumin vaccine

Alpha-lactalbumin vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating alpha-lactalbumin vaccine, 1 is early phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for alpha-lactalbumin vaccine clinical trials.

Invasive breast carcinoma is the most common disease being investigated in alpha-lactalbumin vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Alpha-Lactalbumin Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating alpha-lactalbumin vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.